Tirofiban After Rescue therapy in CVA (Failed Stroke Thrombolysis): A New Opportunity, Not a New Standard
Tirofiban After Rescue therapy in CVA (Failed Stroke Thrombolysis): A New Opportunity, Not a New Standard
The INSTANT trial reported a higher rate of excellent 90-day recovery (63.8% vs 52.2%) when Tirofiban was given after Tenecteplase in selected ischemic stroke patients who failed to show adequate neurological improvement within 4–24 hours, without a significant increase in symptomatic intracranial hemorrhage.
However, this does not mean Tirofiban should be routinely used after thrombolysis.
The benefit was observed in a highly selected population:
• Treated with Tenecteplase.
• Poor early clinical response (who failed to show adequate neurological improvement within 4–24 hours)
• No large-vessel occlusion requiring mechanical thrombectomy.
• No cardioembolic stroke, particularly atrial fibrillation.
Why exclude AF?
Because AF-related thrombi are typically fibrin-rich, where anticoagulation is the cornerstone therapy. In contrast, non-cardioembolic strokes are often associated with platelet-rich thrombi, making potent platelet inhibition with Tirofiban biologically more relevant.
For cardiologists, the concept is familiar.
This is similar to using Tirofiban during primary PCI for STEMI with a large thrombus burden, slow flow, or suboptimal reperfusion. It may be valuable as a bailout or adjunctive strategy, but it is not routinely given to every STEMI patient.
The same principle applies here.
The INSTANT trial supports a potential role for Tirofiban as a rescue therapy after inadequate response to thrombolysis in carefully selected stroke patients, rather than as routine treatment for all ischemic strokes.
At present, the findings are promising, hypothesis-strengthening, and clinically relevant—but not yet practice-changing.
Source: JAMA, June 9, 2026 (Print Issue); published online May 8, 2026.
http://jamanetwork.com/journals/jama/fullarticle/2848809
